growth high end impact
outlook better expect
result outlook broader demand posit commentari
better expect support notion see less net drag
peer less typic compani strong growth
deriv across biopharma custom base biolog key reason
growth rate inflect recent year henc hsd growth
segment construct outlook beyond key reason
like resili remain top pick amongst coverag
busi segment post organ growth ahead pre-covid consensu
instrument heavi segment analyt instrument ai big drag
believ instrument order defer expect larg cancel
industrial/appli academ msd worst hit end
market covid pharma remain solid hsd healthcare/diagnost
also strong quarter ldd china return
normal level expect post covid growth profil
rebound back strong level manag indic notabl
stock benefit result
compani offer wide rang organ flat
manag signal aspir flat even manag offer
biggest driver upsid covid test plan gener
revenu larg sell test kit equat impact
downsid relat custom demand long custom shut
pace open share impact suppli chain none
current total risk gener drag compani provid
margin guidanc difficult quantifi given rang outcom
pt base upon ntm pro-forma deal ep post
deal close
trade data key metric
compani account thomson reuter ub estim ub adjust ep state goodwill-rel charg adjust abnorm econom item analyst
judgement valuat base averag share price year base share price apr edt
report prepar ub secur llc analyst certif requir disclosur begin
page ub seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
million us except per share amount
good
interest expens incom
net incom continu op
million us except per share amount
good
interest expens incom
net incom continu op
profit tax
profit tax
equival
invest asset
trade payabl st liabil
net incom pref div
net chang work capit
chang debt pref share
flow inc/ dec cash
balanc sheet inc/ dec cash
compani account ub estim ub metric use report figur adjust ub ep ub dilut calcul use ub net incom ad back depreci
buy minor
revenu divis us
ebit ub divis us
compani account ub estim ub metric use report figur adjust ub analyst
valuat method risk statement
pt base upon ntm pro-forma deal ep
deal isnt expect close rais pt base upon
ntm pro-forma deal ep previou estim
rise post deal close multipl expans
support expect ep accret deal next
industry-wid risk includ declin spend pharmaceut compani
due signific declin fund small compani promin
trial failur affect class drug deceler global growth
includ risk escal trade tension pressur academ
govern budget could result recessionari cost-cut
polit chang price pressur diagnost sector due
protect access medicar act pama chang competit dynam
includ disrupt new entrant certain technolog inabl
compani compet effect china critic growth market foreign
exchang fluctuat chang tax polici
includ biopharma slow chines economi
risk
integr recent larg make bad strateg decis futur
